Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial
Silk SE. et al, (2024), The Lancet Infectious Diseases, 24, 1105 - 1117
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo MS. et al, (2024), The Lancet, 403, 533 - 544
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults
Silk SE. et al, (2023), Med, 4, 668 - 686.e7
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination
Minassian AM. et al, (2021), Med, 2, 701 - 719.e19
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
Folegatti PM. et al, (2021), Vaccines, 9, 262 - 262
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M. et al, (2020), Vaccine, 38, 779 - 789
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
Folegatti PM. et al, (2019), Vaccines, 7, 40 - 40
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
Venkatraman N. et al, (2019), The Journal of Infectious Diseases, 219, 1187 - 1197
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
Folegatti PM. et al, (2019), Vaccines, 7, 33 - 33
First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
Tiono AB. et al, (2018), PLOS ONE, 13, e0208328 - e0208328
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP
Bliss CM. et al, (2018), Scientific Reports, 8
Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells
Jin J. et al, (2018), npj Vaccines, 3
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
Rampling T. et al, (2018), npj Vaccines, 3
Prime and target immunization protects against liver-stage malaria in mice
Gola A. et al, (2018), Science Translational Medicine, 10, eaap9128 - eaap9128
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
Wajja A. et al, (2018), Wellcome Open Research, 3, 121 - 121
Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154]
Coughlan L. et al, (2018), EBioMedicine, 31, 321 - 321
Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults
Coughlan L. et al, (2018), EBioMedicine, 29, 146 - 154